Taysha Gene Therapies, Inc.

TSHA · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders9.4%

Institutions94.2%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$9.77M	$8.33M	$2.50M	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$110.50M	-$91.46M	-$162.45M	-$173.27M	-$43.00M
Operating income as a percentage of revenue.	-1130.6%	-1097.6%	-6497.9%	–	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$109.00M	-$89.30M	-$166.01M	-$174.52M	-$60.01M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-0.34	$-0.36	$-3.78	$-4.64	$-3.40
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-0.34	$-0.36	$-3.78	–	–

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$319.80M	$139.00M	$87.90M	$149.10M	$251.25M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$343.32M	$160.36M	$126.28M	$213.96M	–
All of the company's interest-bearing borrowings, short and long term combined.	$50.11M	$43.94M	$37.97M	$37.19M	–
Everything the company owes — debt, unpaid bills, and other obligations.	$96.38M	$88.84M	$125.33M	$118.57M	–
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$246.94M	$71.53M	$949000	$95.38M	–

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$93.09M	-$81.22M	-$88.39M	-$117.04M	-$30.73M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$738000	$374000	$20.62M	$15.30M	$82000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$93.83M	-$81.60M	-$109.01M	-$132.35M	-$30.81M

	You	Peer avg
Revenue Growth	–	+55.6%
ROE	-47.1%	-62.9%

Taysha Gene Therapies, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison